Aptar Reports Third Quarter 2022 Results

Aptar Reports Third Quarter 2022 Results




Aptar Reports Third Quarter 2022 Results

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today reported net income of $54 million for the quarter ended September 30, 2022, a 15% increase over the prior year. Reported sales grew 1% and core sales, excluding currency and acquisition effects, increased by 9% over the prior year.


“Aptar performed well during the third quarter, delivering solid results while continuing to adapt to a challenging and uncertain economic backdrop. Our Pharma segment saw double-digit core sales growth, led by its prescription, consumer healthcare and active materials divisions. Beauty + Home had strong growth in Europe, especially in fragrance, but continued to be impacted by supply chain and labor issues in North America. Core sales in Food + Beverage were flat due to difficult comparisons with the prior year period, and were impacted by softening demand, especially in North America as our customers work off their inventory,” said Stephan B. Tanda, President and CEO, Aptar.

Third Quarter 2022 Summary

  • Reported sales grew 1% and net income increased 15% to $54 million
  • Core sales increased 9% and adjusted EBITDA was even with the prior year level of $154 million
  • Reported earnings per share increased 16% to $0.81 compared to $0.70 in the prior year
  • Adjusted earnings per share increased 12% to $0.95 compared to $0.85 in the prior year (including comparable exchange rates)
  • Strong sales growth in the quarter driven by strong volume growth in Pharma
  • Adjusted earnings per share includes a previously announced one-time inflation payment to certain European employees of approximately 5 cents per share
  • Tax rate of 36% includes a one-time tax charge related to legal entity reorganization; without this charge our tax rate would have been 28%

Third Quarter Results

For the quarter ended September 30, 2022, reported sales increased 1% to $837 million compared to $825 million in the prior year. Core sales, excluding the impact from changes in currency exchange rates and acquisitions, increased 9%.

Third Quarter Segment Sales Analysis

(Change Over Prior Year)

 

Pharma

Beauty +

Home

Food +

Beverage

Total

AptarGroup

Core Sales Growth

20

%

4

%

0

%

9

%

Acquisitions

1

%

0

%

0

%

0

%

Currency Effects (1)

(11

%)

(8

%)

(3

%)

(8

%)

Total Reported Sales Growth

10

%

(4

%)

(3

%)

1

%

 

(1) – Currency effects are approximated by translating last year’s amounts at this year’s foreign exchange rates.

Aptar’s Pharma segment had strong double-digit core sales growth driven primarily by significant demand from the prescription, consumer healthcare and active material markets. Sales growth benefited by the rebounding of allergies and increases in common colds across a wide variety of applications as well as an increase in asthma therapies. Increased demand for our devices used in emergency medical applications also contributed to our growth.

Aptar’s Beauty + Home segment continued to benefit from pricing initiatives and increased demand for prestige fragrance, sunscreen and hair care applications as a result of increased mobility and travel. Europe achieved strong growth in the quarter offset by declines in other regions, especially in North America due to ongoing labor shortages and supply chain issues, and in Asia where sporadic related lockdowns affected demand.

Core sales for Aptar’s Food + Beverage segment were even with the prior year, due to the difficult comparisons after a period of substantial growth in 2021. Volumes in the food and beverage markets decreased, primarily driven by weaker demand in North America, as customers work through their inventories. These decreases partially were offset by higher custom tooling sales, which typically have lower margins, and price increase initiatives.

Aptar reported third quarter earnings per share of $0.81, an increase of 16%, compared to $0.70 during the same period a year ago. Third quarter adjusted earnings per share, excluding restructuring charges, acquisition costs, a tax charge related to a legal entity reorganization and the unrealized gains or losses on an equity investment, were $0.95, an increase of 12%, compared to $0.85 in the prior year, including comparable exchange rates.

Year-to-Date Results

For the nine months ended September 30, 2022, reported sales increased 5% to $2.53 billion compared to $2.41 billion in the prior year. Core sales, excluding the impact from changes in currency exchange rates and acquisitions, increased 11%.

Nine Months Year-To-Date Segment Sales Analysis

(Change Over Prior Year)

 

Pharma

Beauty +

Home

Food +

Beverage

Total

AptarGroup

Core Sales Growth

15

%

8

%

8

%

11

%

Acquisitions

1

%

0

%

0

%

0

%

Currency Effects (1)

(8

)%

(6

)%

(2

)%

(6

)%

Total Reported Sales Growth

8

%

2

%

6

%

5

%

 

(1) – Currency effects are approximated by translating last year’s amounts at this year’s foreign exchange rates.

For the nine months ended September 30, 2022, Aptar’s reported earnings per share were $2.70, a decrease of 2%, compared to $2.75 reported a year ago. Current year adjusted earnings per share, excluding restructuring charges, acquisition costs, a tax charge related to a legal entity reorganization and the unrealized gains or losses on an equity investment, were $2.87 and increased 5% from prior year adjusted earnings per share of $2.74, including comparable exchange rates. The prior year’s adjusted earnings included an effective tax rate of 23% (approximately $0.19 cents per share impact compared to current period effective tax rate of 28%).

Outlook

Regarding Aptar’s outlook, Tanda stated, “Looking to the fourth quarter, our Pharma segment is expected to continue to grow at more normalized levels, however, we do not expect to repeat last year’s strong sales of active material solutions for at-home COVID-19 test kits. We anticipate the softening in demand in markets such as personal care, food and beverage to continue. We remain focused on managing the inflationary environment through price initiatives and energy surcharges, as well as controlling expenses. We will continue to allocate capital selectively while maintaining our strong balance sheet.”

Aptar expects earnings per share for the fourth quarter of 2022, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $0.73 to $0.83. This guidance is based on an effective tax rate range of 28% to 30% which compares to an effective tax rate of 28% on prior year adjusted earnings. The earnings per share guidance range was based on a Euro/US$ exchange rate of 0.98 and the spot rates at the end of September for all other currencies. Our currency exchange rate assumptions equate to an approximately $0.08 per share headwind when compared to the prior year fourth quarter earnings.

Cash Dividends and Share Repurchases

As previously announced, Aptar’s Board of Directors declared a quarterly cash dividend of $0.38 per share. The payment date is November 16, 2022, to stockholders of record as of October 26, 2022. With this dividend, Aptar will have completed its 29th consecutive year of paying an increased annual dividend total to stockholders. During the third quarter, Aptar repurchased 181 thousand shares for approximately $19 million, leaving $128 million authorized for common stock repurchases at the end of the third quarter. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

Open Conference Call

There will be a conference call held on Friday, October 28, 2022 at 8:00 a.m. Central Time to discuss the Company’s third quarter results for 2022. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of business transformation charges (restructuring initiatives), acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year, and adjusted earnings per share further adjusts for the net effect of a tax payment related to a legal entity reorganization. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the Company’s routine activities, such as restructuring and acquisition costs.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; the impact of COVID-19 and its variants on our global supply chain and our global customers, employees and operations, which has elevated and will continue to elevate many of the risks and uncertainties discussed below; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; the availability of direct labor workers and the increase in direct labor costs, especially in North America; our ability to preserve organizational culture and maintain employee productivity in the work-from-home environment caused by the current pandemic; the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs); significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to successfully implement facility expansions and new facility projects; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired, including contingent consideration valuation; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; cybersecurity threats that could impact our networks and reporting systems; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes or difficulties in complying with government regulation; changing regulations or market conditions regarding environmental sustainability; work stoppages due to labor disputes; competition, including technological advances; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(In Thousands, Except Per Share Data)

Consolidated Statements of Income

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

 

 

 

 

 

 

 

 

Net Sales

$

836,860

 

 

$

825,442

 

 

$

2,526,335

 

 

$

2,413,228

 

Cost of Sales (exclusive of depreciation and amortization shown below)

 

546,376

 

 

 

537,085

 

 

 

1,638,114

 

 

 

1,548,840

 

Selling, Research & Development and Administrative

 

135,428

 

 

 

135,931

 

 

 

416,351

 

 

 

411,192

 

Depreciation and Amortization

 

57,601

 

 

 

59,280

 

 

 

174,818

 

 

 

174,508

 

Restructuring Initiatives

 

2,270

 

 

 

10,223

 

 

 

2,989

 

 

 

18,771

 

Operating Income

 

95,185

 

 

 

82,923

 

 

 

294,063

 

 

 

259,917

 

Other Income (Expense):

 

 

 

 

 

 

 

Interest Expense

 

(9,756

)

 

 

(8,011

)

 

 

(30,668

)

 

 

(22,601

)

Interest Income

 

752

 

 

 

401

 

 

 

2,029

 

 

 

1,406

 

Net Investment Gain (Loss)

 

649

 

 

 

(9,021

)

 

 

(1,084

)

 

 

6,177

 

Equity in Results of Affiliates

 

178

 

 

 

(71

)

 

 

(184

)

 

 

(505

)

Miscellaneous, net

 

(2,093

)

 

 

13

 

 

 

(3,144

)

 

 

(2,978

)

Income before Income Taxes

 

84,915

 

 

 

66,234

 

 

 

261,012

 

 

 

241,416

 

Provision for Income Taxes

 

30,738

 

 

 

19,340

 

 

 

80,851

 

 

 

55,309

 

Net Income

$

54,177

 

 

$

46,894

 

 

$

180,161

 

 

$

186,107

 

Net Loss Attributable to Noncontrolling Interests

 

67

 

 

 

366

 

 

 

131

 

 

 

381

 

Net Income Attributable to AptarGroup, Inc.

$

54,244

 

 

$

47,260

 

 

$

180,292

 

 

$

186,488

 

Net Income Attributable to AptarGroup, Inc. per Common Share:

 

 

 

 

 

 

 

Basic

$

0.83

 

 

$

0.72

 

 

$

2.75

 

 

$

2.84

 

Diluted

$

0.81

 

 

$

0.70

 

 

$

2.70

 

 

$

2.75

 

 

 

 

 

 

 

 

 

Average Numbers of Shares Outstanding:

 

 

 

 

 

 

 

Basic

 

65,322

 

 

 

65,900

 

 

 

65,446

 

 

 

65,652

 

Diluted

 

66,581

 

 

 

67,801

 

 

 

66,825

 

 

 

67,799

 

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Balance Sheets

 

 

September 30,

2022

 

December 31,

2021

ASSETS

 

 

 

 

 

 

 

Cash and Equivalents

$

124,812

 

$

122,925

Short-term Investments

 

 

 

740

Total Cash and Equivalents, and Short-term Investments

 

124,812

 

 

123,665

Accounts and Notes Receivable, Net

 

690,818

 

 

671,350

Inventories

 

462,752

 

 

441,464

Prepaid and Other Current Assets

 

121,352

 

 

121,729

Total Current Assets

 

1,399,734

 

 

1,358,208

Property, Plant and Equipment, Net

 

1,225,800

 

 

1,275,877

Goodwill

 

910,041

 

 

974,157

Other Assets

 

490,897

 

 

533,122

Total Assets

$

4,026,472

 

$

4,141,364

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

 

Short-Term Obligations

$

164,243

 

$

289,627

Accounts Payable, Accrued and Other Liabilities

 

732,409

 

 

692,865

Total Current Liabilities

 

896,652

 

 

982,492

Long-Term Obligations

 

1,028,048

 

 

907,024

Deferred Liabilities and Other

 

213,647

 

 

267,248

Total Liabilities

 

2,138,347

 

 

2,156,764

 

 

 

 

AptarGroup, Inc. Stockholders’ Equity

 

1,874,682

 

 

1,969,407

Noncontrolling Interests in Subsidiaries

 

13,443

 

 

15,193

Total Equity

 

1,888,125

 

 

1,984,600

 

 

 

 

Total Liabilities and Equity

$

4,026,472

 

$

4,141,364

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

 

 

Three Months Ended

September 30, 2022

 

 

 

Consolidated

 

 

Pharma

 

Beauty +

Home

 

Food +

Beverage

 

Corporate

& Other

 

Net Interest

Net Sales

$

836,860

 

 

 

$

343,397

 

 

$

359,823

 

 

$

133,640

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income

$

54,177

 

 

 

 

 

 

 

 

 

 

 

 

Reported income taxes

 

30,738

 

 

 

 

 

 

 

 

 

 

 

 

Reported income before income taxes

 

84,915

 

 

 

 

83,571

 

 

 

16,184

 

 

 

9,005

 

 

 

(14,841

)

 

 

(9,004

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring initiatives

 

2,270

 

 

 

 

 

 

 

2,344

 

 

 

(74

)

 

 

 

 

 

Net unrealized investment gain

 

(277

)

 

 

 

 

 

 

 

 

 

 

 

 

(277

)

 

 

Transaction costs related to acquisitions

 

231

 

 

 

 

231

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings before income taxes

 

87,139

 

 

 

 

83,802

 

 

 

18,528

 

 

 

8,931

 

 

 

(15,118

)

 

 

(9,004

)

Interest expense

 

9,756

 

 

 

 

 

 

 

 

 

 

 

 

9,756

 

Interest income

 

(752

)

 

 

 

 

 

 

 

 

 

 

 

(752

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

96,143

 

 

 

 

83,802

 

 

 

18,528

 

 

 

8,931

 

 

 

(15,118

)

 

 

 

Depreciation and amortization

 

57,601

 

 

 

 

23,433

 

 

 

22,702

 

 

 

9,885

 

 

 

1,581

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

153,744

 

 

 

$

107,235

 

 

$

41,230

 

 

$

18,816

 

 

$

(13,537

)

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

18.4

%

 

 

 

31.2

%

 

 

11.5

%

 

 

14.1

%

 

 

 

 

 

Three Months Ended

September 30, 2021

 

 

 

Consolidated

 

 

Pharma

 

Beauty +

Home

 

Food +

Beverage

 

Corporate

& Other

 

Net Interest

Net Sales

$

825,442

 

 

 

$

313,225

 

 

$

374,088

 

 

$

138,129

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income

$

46,894

 

 

 

 

 

 

 

 

 

 

 

 

Reported income taxes

 

19,340

 

 

 

 

 

 

 

 

 

 

 

 

Reported income before income taxes

 

66,234

 

 

 

 

75,611

 

 

 

14,443

 

 

 

12,027

 

 

 

(28,237

)

 

 

(7,610

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring initiatives

 

10,223

 

 

 

 

13

 

 

 

5,442

 

 

 

131

 

 

 

4,637

 

 

 

Net unrealized investment loss

 

9,021

 

 

 

 

 

 

 

 

 

 

 

 

 

9,021

 

 

 

Transaction costs related to acquisitions

 

1,793

 

 

 

 

1,793

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings before income taxes

 

87,271

 

 

 

 

77,417

 

 

 

19,885

 

 

 

12,158

 

 

 

(14,579

)

 

 

(7,610

)

Interest expense

 

8,011

 

 

 

 

 

 

 

 

 

 

 

 

8,011

 

Interest income

 

(401

)

 

 

 

 

 

 

 

 

 

 

 

(401

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

94,881

 

 

 

 

77,417

 

 

 

19,885

 

 

 

12,158

 

 

 

(14,579

)

 

 

 

Depreciation and amortization

 

59,280

 

 

 

 

23,321

 

 

 

23,904

 

 

 

10,221

 

 

 

1,834

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

154,161

 

 

 

$

100,738

 

 

$

43,789

 

 

$

22,379

 

 

$

(12,745

)

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

18.7

%

 

 

 

32.2

%

 

 

11.7

%

 

 

16.2

%

 

 

 

 

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

 

 

Nine Months Ended

September 30, 2022

 

 

 

Consolidated

 

 

Pharma

 

Beauty +

Home

 

Food +

Beverage

 

Corporate

& Other

 

Net Interest

Net Sales

$

2,526,335

 

 

 

$

1,026,090

 

 

$

1,099,368

 

 

$

400,877

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income

$

180,161

 

 

 

 

 

 

 

 

 

 

 

 

Reported income taxes

 

80,851

 

 

 

 

 

 

 

 

 

 

 

 

Reported income before income taxes

 

261,012

 

 

 

 

263,222

 

 

 

52,918

 

 

 

25,572

 

 

 

(52,061

)

 

 

(28,639

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring initiatives

 

2,989

 

 

 

 

 

 

 

3,022

 

 

 

(33

)

 

 

 

 

 

Net unrealized investment loss

 

2,297

 

 

 

 

 

 

 

 

 

 

 

 

 

2,297

 

 

 

Transaction costs related to acquisitions

 

231

 

 

 

 

231

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings before income taxes

 

266,529

 

 

 

 

263,453

 

 

 

55,940

 

 

 

25,539

 

 

 

(49,764

)

 

 

(28,639

)

Interest expense

 

30,668

 

 

 

 

 

 

 

 

 

 

 

 

30,668

 

Interest income

 

(2,029

)

 

 

 

 

 

 

 

 

 

 

 

(2,029

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

295,168

 

 

 

 

263,453

 

 

 

55,940

 

 

 

25,539

 

 

 

(49,764

)

 

 

 

Depreciation and amortization

 

174,818

 

 

 

 

70,340

 

 

 

69,667

 

 

 

30,217

 

 

 

4,594

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

469,986

 

 

 

$

333,793

 

 

$

125,607

 

 

$

55,756

 

 

$

(45,170

)

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

18.6

%

 

 

 

32.5

%

 

 

11.4

%

 

 

13.9

%

 

 

 

 

Contacts

Investor Relations Contact:
Mary Skafidas

mary.skafidas@aptar.com
815-479-5658

Media Contact:
Katie Reardon

katie.reardon@aptar.com
815-479-5671

Read full story here